NCT02718846已完成4 期
A Multicenter, Randomized, Open-label Clinical Study With a Concurrent Control Group to Assess the Effectiveness and Safety of Combined Therapy With Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets for Patients With Meniere's Disease
Alvogen Korea0 个研究点目标入组 220 人开始时间: 2013年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 220
- 主要终点
- the number of vertigo episodes
研究概览
简要总结
A multicenter, randomized, open-label clinical study with a concurrent control group to assess the effectiveness and safety of combined therapy with Isobide solution and Meniace tablets compared to monotherapy with Meniace tablets for patients with Meniere's disease
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •20 - 80 years of age (in full)
- •A definite Meniere's disease patient according to the diagnostic criteria of AAO-HNS (1995), who has had 2 or more episodes of rotary dizziness lasting more than 20 minutes within the last 3 months (12 weeks) and 1 or more episodes of hearing loss recorded by audiometry, and has tinnitus or ear fullness.
- •For female subjects with the possibility of pregnancy during the study period, a subject whose urine pregnancy test result was negative at the time of the screening visit. A subject in menopause for at least one year, one who has no possibility to become pregnant through surgery, or one who effectively uses an acceptable contraceptive measure. A subject who definitely agreed to use an adequate contraceptive measure during the clinical study period.
排除标准
- •A patient with the history of ear surgery
- •A patient with the history of endolymphatic sac surgery
- •A patient who used steroids or gentamycin in the eardrum within the last 6 months
- •A patient to whom Isobide was administered within 3 months at the time of screening
- •A patient who has an infection in the ear, paranasal sinuses or the upper airway system
- •A patient who has a disease, other than Meniere's disease, that manifests as repetitive dizziness (e.g. Migrainous vertigo, vertebrobasilar transient ischemic attack, acoustic neuroma)
- •A patient who has acute intracranial hematoma (If this drug is administered to a patient suspected of having an acute intracranial hematoma without checking for the existence of an intracranial hematoma, bleeding that had been stopped temporarily by brain pressure can occur again when intracranial pressure is reduced. Thus, eliminate the cause of bleeding and administer the drug after ensuring that there are no concerns of rebleeding)
- •A patient with anuria (with urinary output of less than 100 mL/day)
- •A severely dehydrated patient (loss of 10% or more of body weight)
- •A patient with acute pulmonary edema
- •A patient with severe heart failure (New York Heart Association class III or higher)
- •A patient with an adrenal tumor
- •A patient with pheochromocytoma
- •A patient who is hypersensitive to the ingredients of the test and control drugs
- •A patient with a hereditary disease such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption
- •A woman who is pregnant or breastfeeding
- •A patient who is deemed ineligible for this clinical study by the analyst
研究组 & 干预措施
Meniace and Isobide
Experimental
co-administration Isobide solution and Meniace tablets
干预措施: Meniace (Drug)
Meniace and Isobide
Experimental
co-administration Isobide solution and Meniace tablets
干预措施: Isobide (Drug)
Meniace
Active Comparator
single administration Meniace tablets
干预措施: Meniace (Drug)
结局指标
主要结局
the number of vertigo episodes
时间窗: The difference between the number of vertigo episodes experienced during the 4 weeks before the screening and the number of vertigo episodes during the 4 weeks after administration of the study drug
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) TreatmentRheumatoid ArthritisNCT01468077Hoffmann-La Roche47
招募中
3 期
Study of LY01610 in Patients With Recurrent Small Cell Lung CancerRelapsed Small Cell Lung CancerNCT06128837Luye Pharma Group Ltd.686
尚未招募
2 期
A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastNCT03854617Chinese Academy of Medical Sciences172
已完成
不适用
OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use DisorderOpioid-use DisorderNCT04948307Orexo AB437
已完成
3 期
Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)LeukopeniaNCT00811928Merck Sharp & Dohme LLC252